GeneDx (WGS) Competitors

Guardant Health (NASDAQ:GH) and GeneDx (NASDAQ:WGS) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, community ranking, profitability, earnings, analyst recommendations, valuation and risk.

Does the media refer more to GH or WGS?

In the previous week, Guardant Health and Guardant Health both had 21 articles in the media. Guardant Health's average media sentiment score of 0.54 beat GeneDx's score of 0.28 indicating that Guardant Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Guardant Health	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive
GeneDx	4 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Do analysts rate GH or WGS?

Guardant Health presently has a consensus target price of $44.78, indicating a potential upside of 4.45%. GeneDx has a consensus target price of $72.33, indicating a potential downside of 24.52%. Given Guardant Health's stronger consensus rating and higher possible upside, equities research analysts clearly believe Guardant Health is more favorable than GeneDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Guardant Health	0 Sell rating(s)	0 Hold rating(s)	18 Buy rating(s)	0 Strong Buy rating(s)	3.00
GeneDx	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

Does the MarketBeat Community favor GH or WGS?

Guardant Health received 277 more outperform votes than GeneDx when rated by MarketBeat users. Likewise, 70.59% of users gave Guardant Health an outperform vote while only 47.83% of users gave GeneDx an outperform vote.

Company	Underperform	Outperform
Guardant Health	Outperform Votes 288 70.59%	Underperform Votes 120 29.41%
GeneDx	Outperform Votes 11 47.83%	Underperform Votes 12 52.17%

Which has higher earnings and valuation, GH or WGS?

GeneDx has lower revenue, but higher earnings than Guardant Health. GeneDx is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Guardant Health	$563.95M	9.39	-$479.45M	-$4.24	-10.11
GeneDx	$305.45M	8.62	-$175.77M	-$1.96	-48.89

Is GH or WGS more profitable?

GeneDx has a net margin of -17.12% compared to Guardant Health's net margin of -74.02%. GeneDx's return on equity of 3.33% beat Guardant Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Guardant Health	-74.02%	-1,200.44%	-29.88%
GeneDx	-17.12%	3.33%	1.69%

Which has more risk & volatility, GH or WGS?

Guardant Health has a beta of 1.32, meaning that its share price is 32% more volatile than the S&P 500. Comparatively, GeneDx has a beta of 2.01, meaning that its share price is 101% more volatile than the S&P 500.

Do insiders and institutionals have more ownership in GH or WGS?

92.6% of Guardant Health shares are held by institutional investors. Comparatively, 61.7% of GeneDx shares are held by institutional investors. 5.5% of Guardant Health shares are held by company insiders. Comparatively, 27.3% of GeneDx shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Summary

Guardant Health beats GeneDx on 10 of the 17 factors compared between the two stocks.